Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
770
Trial Sponsor
Clinical Trial Start Date
March 21, 2022
0Primary Completion Date
June 30, 2023
0Study Completion Date
June 30, 2024
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Biological0
Intervention Name
ALVR1060
Placebo0
Interventional Trial Phase
Phase 10
Phase 20
Participating Facility
Official Name
Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients With Respiratory Viral Infections After Hematopoietic Cell Transplant0
Last Updated
April 19, 2022
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Quadruple0
Masked Party
Participant0
Investigator0
Outcomes Assessor0
Care Provider0
Study summary
A study to evaluate ALVR106; an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets four community acquired respiratory viruses: respiratory syncytial virus (RSV), influenza, human metapneumovirus (hMPV), and/or parainfluenza virus (PIV) following hematopoietic cell transplant (HCT)
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
